These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19353475)

  • 1. [Acceptance and safety of vaccines].
    Bartz H; von Knebel-Döberitz M
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S71-6. PubMed ID: 19353475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical safety issues of measles, mumps and rubella vaccines.
    Afzal MA; Minor PD; Schild GC
    Bull World Health Organ; 2000; 78(2):199-204. PubMed ID: 10743285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parental vaccine concerns in Kentucky.
    Smith MJ; Woods CR; Marshall GS
    J Ky Med Assoc; 2009 Sep; 107(9):342-9. PubMed ID: 19813430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination and immunization in healthcare workers, towards specific infections: measles, varicella, rubella and mumps. The experience in a hospital in Lombardy].
    Cologni L; Belotti L; Bacis M; Bigoni F; Grigis A; Passerini C; Locati F; Mosconi G
    G Ital Med Lav Ergon; 2007; 29(3 Suppl):413-4. PubMed ID: 18409751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autism, viral infection and measles-mumps-rubella vaccination.
    Wakefield AJ; Montgomery SM
    Isr Med Assoc J; 1999 Nov; 1(3):183-7. PubMed ID: 10731332
    [No Abstract]   [Full Text] [Related]  

  • 9. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overview of measles, mumps, rubella and varicella vaccination in adolescents and adults].
    Quast U; Arndt U
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S77-81. PubMed ID: 19353476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current controversies in the USA regarding vaccine safety.
    Chatterjee A; O'Keefe C
    Expert Rev Vaccines; 2010 May; 9(5):497-502. PubMed ID: 20450324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Vaccine Safety Datalink project.
    DeStefano F;
    Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of serious neurologic disease after immunization of young children in Britain and Ireland.
    Ward KN; Bryant NJ; Andrews NJ; Bowley JS; Ohrling A; Verity CM; Ross EM; Miller E
    Pediatrics; 2007 Aug; 120(2):314-21. PubMed ID: 17671057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mumps vaccine virus strains and aseptic meningitis.
    Bonnet MC; Dutta A; Weinberger C; Plotkin SA
    Vaccine; 2006 Nov; 24(49-50):7037-45. PubMed ID: 16884835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and future use of viral vaccines in Israel.
    Swartz TA
    Isr J Med Sci; 1983 Nov; 19(11):1016-20. PubMed ID: 6662684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, mumps, and rubella: prevention.
    Booy R; Sengupta N; Bedford H; Elliman D
    Clin Evid; 2006 Jun; (15):448-68. PubMed ID: 16973018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.